EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

I. Elovaara; S. Apostolski; P. van Doorn; N.E. Gilhus; A. Hietaharju; J. Honkaniemi; Schaik,I van; N. Scolding; B. Udd; Per Soelberg Sørensen

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

I. Elovaara, S. Apostolski, P. van Doorn, N.E. Gilhus, A. Hietaharju, J. Honkaniemi, Schaik,I van, N. Scolding, B. Udd, Per Soelberg Sørensen

213 Citationer (Scopus)

Abstract

Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, the recent papers of high relevance were reviewed and consensus recommendations are given according to EFNS guidance regulations. The efficacy of IVIG has been proven in Guillain-Barre syndrome (level A), chronic inflammatory demyelinating polyradiculoneuropathy (level A), multifocal mononeuropathy (level A), acute exacerbations of myasthenia gravis (MG) and short-term treatment of severe MG (level A recommendation), and some paraneoplastic neuropathies (level B). IVIG is recommended as a second-line treatment in combination with prednisone in dermatomyositis (level B) and treatment option in polymyositis (level C). IVIG should be considered as a second or third-line therapy in relapsing-remitting multiple sclerosis, if conventional immunomodulatory therapies are not tolerated (level B), and in relapses during pregnancy or post-partum period (good clinical practice point). IVIG seems to have a favourable effect also in paraneoplastic neurological diseases (level A), stiff-person syndrome (level A), some acute-demyelinating diseases and childhood refractory epilepsy (good practice point)
Udgivelsesdato: 2008/9

Originalsprog	Engelsk
Tidsskrift	European Journal of Neurology
Vol/bind	15
Udgave nummer	9
Sider (fra-til)	893-908
Antal sider	15
ISSN	1351-5101
Status	Udgivet - 2008

Citationsformater

Elovaara, I., Apostolski, S., Doorn, P. V., Gilhus, N. E., Hietaharju, A., Honkaniemi, J., van, SI., Scolding, N., Udd, B., & Sørensen, P. S. (2008). EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology, 15(9), 893-908.

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. / Elovaara, I.; Apostolski, S.; Doorn, P. van et al.

I: European Journal of Neurology, Bind 15, Nr. 9, 2008, s. 893-908.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Elovaara, I, Apostolski, S, Doorn, PV, Gilhus, NE, Hietaharju, A, Honkaniemi, J, van, SI, Scolding, N, Udd, B & Sørensen, PS 2008, 'EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases', European Journal of Neurology, bind 15, nr. 9, s. 893-908.

@article{f131f800986b11de8bc9000ea68e967b,

title = "EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases",

abstract = "Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, the recent papers of high relevance were reviewed and consensus recommendations are given according to EFNS guidance regulations. The efficacy of IVIG has been proven in Guillain-Barre syndrome (level A), chronic inflammatory demyelinating polyradiculoneuropathy (level A), multifocal mononeuropathy (level A), acute exacerbations of myasthenia gravis (MG) and short-term treatment of severe MG (level A recommendation), and some paraneoplastic neuropathies (level B). IVIG is recommended as a second-line treatment in combination with prednisone in dermatomyositis (level B) and treatment option in polymyositis (level C). IVIG should be considered as a second or third-line therapy in relapsing-remitting multiple sclerosis, if conventional immunomodulatory therapies are not tolerated (level B), and in relapses during pregnancy or post-partum period (good clinical practice point). IVIG seems to have a favourable effect also in paraneoplastic neurological diseases (level A), stiff-person syndrome (level A), some acute-demyelinating diseases and childhood refractory epilepsy (good practice point) Udgivelsesdato: 2008/9",

author = "I. Elovaara and S. Apostolski and Doorn, {P. van} and N.E. Gilhus and A. Hietaharju and J. Honkaniemi and Schaik,I van and N. Scolding and B. Udd and S{\o}rensen, {Per Soelberg}",

year = "2008",

language = "English",

volume = "15",

pages = "893--908",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

AU - Elovaara, I.

AU - Apostolski, S.

AU - Doorn, P. van

AU - Gilhus, N.E.

AU - Hietaharju, A.

AU - Honkaniemi, J.

AU - van, Schaik,I

AU - Scolding, N.

AU - Udd, B.

AU - Sørensen, Per Soelberg

PY - 2008

Y1 - 2008

N2 - Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, the recent papers of high relevance were reviewed and consensus recommendations are given according to EFNS guidance regulations. The efficacy of IVIG has been proven in Guillain-Barre syndrome (level A), chronic inflammatory demyelinating polyradiculoneuropathy (level A), multifocal mononeuropathy (level A), acute exacerbations of myasthenia gravis (MG) and short-term treatment of severe MG (level A recommendation), and some paraneoplastic neuropathies (level B). IVIG is recommended as a second-line treatment in combination with prednisone in dermatomyositis (level B) and treatment option in polymyositis (level C). IVIG should be considered as a second or third-line therapy in relapsing-remitting multiple sclerosis, if conventional immunomodulatory therapies are not tolerated (level B), and in relapses during pregnancy or post-partum period (good clinical practice point). IVIG seems to have a favourable effect also in paraneoplastic neurological diseases (level A), stiff-person syndrome (level A), some acute-demyelinating diseases and childhood refractory epilepsy (good practice point) Udgivelsesdato: 2008/9

AB - Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, the recent papers of high relevance were reviewed and consensus recommendations are given according to EFNS guidance regulations. The efficacy of IVIG has been proven in Guillain-Barre syndrome (level A), chronic inflammatory demyelinating polyradiculoneuropathy (level A), multifocal mononeuropathy (level A), acute exacerbations of myasthenia gravis (MG) and short-term treatment of severe MG (level A recommendation), and some paraneoplastic neuropathies (level B). IVIG is recommended as a second-line treatment in combination with prednisone in dermatomyositis (level B) and treatment option in polymyositis (level C). IVIG should be considered as a second or third-line therapy in relapsing-remitting multiple sclerosis, if conventional immunomodulatory therapies are not tolerated (level B), and in relapses during pregnancy or post-partum period (good clinical practice point). IVIG seems to have a favourable effect also in paraneoplastic neurological diseases (level A), stiff-person syndrome (level A), some acute-demyelinating diseases and childhood refractory epilepsy (good practice point) Udgivelsesdato: 2008/9

M3 - Journal article

SN - 1351-5101

VL - 15

SP - 893

EP - 908

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 9

ER -